Exact Mass: 317.2272

Exact Mass Matches: 317.2272

Found 230 metabolites which its exact mass value is equals to given mass value 317.2272, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Nateglinide

(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid

C19H27NO3 (317.1991)


Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naive to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83\\%) and feces (10\\%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound. C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents

   

HEXOCYCLIUM

HEXOCYCLIUM

C20H33N2O+ (317.2593)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AB - Synthetic anticholinergics, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

Butenafine

N-4-Tert-butylbenzyl-N-methyl-1-naphthalene methylamine hydrochloride

C23H27N (317.2143)


Butenafine is only found in individuals that have used or taken this drug. It is a synthetic benzylamine antifungal agent.Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells. D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

   

Funtumine

3alpha-amino-5alpha-pregnan-20-one

C21H35NO (317.2719)


   

Tetrabenazine

9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one

C19H27NO3 (317.1991)


A drug formerly used as an antipsychotic but now used primarily in the treatment of various movement disorders including tardive dyskinesia. Tetrabenazine blocks uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system. [PubChem] D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators N - Nervous system Same as: D08575

   

protoemetine

Ipecac (Protoemetine)

C19H27NO3 (317.1991)


   

MLS002608010

17beta-Hydroxy-4,17-dimethyl-4-azaandrost-5-en-3-one

C20H31NO2 (317.2355)


   

Glycopyrrolate

Glycopyrrolate

C19H27NO3 (317.1991)


   

3-hydroxynonanoyl carnitine

3-[(3-hydroxynonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO5 (317.2202)


3-Hydroxynonanoyl carnitine is an acylcarnitine. More specifically, it is an 3-hydroxynonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxynonanoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxynonanoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Suberoyl-L-carnitine

4-[(7-Carboxyheptanoyl)oxy]-4-(trimethylammonio)butanoic acid

C15H27NO6 (317.1838)


Suberoyl-L-carnitine is an acylcarnitine. More specifically, it is an suberoic aicd ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Suberoyl-L-carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Suberoyl-L-carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-methylheptanedioylcarnitine

3-[(6-carboxy-3-methylhexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


3-methylheptanedioylcarnitine is an acylcarnitine. More specifically, it is an 3-methylheptanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-methylheptanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-methylheptanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2,4-dimethylhexanedioylcarnitine

3-[(5-carboxy-3,5-dimethylpentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


2,4-dimethylhexanedioylcarnitine is an acylcarnitine. More specifically, it is an 2,4-dimethylhexanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2,4-dimethylhexanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2,4-dimethylhexanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octanedioylcarnitine

3-[(7-carboxyheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


Octanedioylcarnitine is an acylcarnitine. More specifically, it is an octanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular octanedioylcarnitine is elevated in the blood or plasma of individuals with pulmonary arterial hypertension (PMID: 32108049) and type 2 diabetes mellitus (PMID: 19369366). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Morpholine, 4-(3-(4-(1,1-dimethylpropyl)phenyl)-2-methylpropyl)-2,6-dimethyl-

Morpholine, 4-(3-(4-(1,1-dimethylpropyl)phenyl)-2-methylpropyl)-2,6-dimethyl-

C21H35NO (317.2719)


D000890 - Anti-Infective Agents > D000935 - Antifungal Agents

   

2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate

2-(Morpholin-4-yl)ethyl 1-phenylcyclohexane-1-carboxylic acid

C19H27NO3 (317.1991)


   
   

Acetyllobscurinol

Acetyllobscurinol

C19H27NO3 (317.1991)


   

Wrightiamine B

Wrightiamine B

C21H35NO (317.2719)


   
   

drofenine

drofenine

C20H31NO2 (317.2355)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   
   

(2E,4E,9Z)-1-(piperidin-1-yl)hexadeca-2,4,9-trien-1-one

(2E,4E,9Z)-1-(piperidin-1-yl)hexadeca-2,4,9-trien-1-one

C21H35NO (317.2719)


   

Ac-(E)-6-[2-(1-Hydroxybutyl)-4-methylphenyl]-5-hexenamide

Ac-(E)-6-[2-(1-Hydroxybutyl)-4-methylphenyl]-5-hexenamide

C19H27NO3 (317.1991)


   
   

Holafebrine

Holafebrine

C21H35NO (317.2719)


   
   
   

glaciapyrrole B

glaciapyrrole B

C19H27NO3 (317.1991)


   
   

C1=CC=C2C3=CC=C4OC(CCC=C(C)C)(C)C=CC4=C3NC2=C1

C1=CC=C2C3=CC=C4OC(CCC=C(C)C)(C)C=CC4=C3NC2=C1

C22H23NO (317.178)


   

1-(1,2,3,4,5,6,7,10-octahydro-4,4,10-trimethyl-8H-benzo[e]indol-2-yl)-3-hydroxy-3-methylbutan-2-one|chamobtusin A

1-(1,2,3,4,5,6,7,10-octahydro-4,4,10-trimethyl-8H-benzo[e]indol-2-yl)-3-hydroxy-3-methylbutan-2-one|chamobtusin A

C20H31NO2 (317.2355)


   

cavernene B

cavernene B

C21H35NO (317.2719)


   

mycalazal-16

mycalazal-16

C21H35NO (317.2719)


   

(7aS,11aS,11bS)-7,7a,8,9,10,11,11a,11b-octahydro-11b-hydroxy-alpha,alpha,8,8,11a-pentamethyl-6H-naphth[1,2-d]azepine-4-methanol|triptotin J

(7aS,11aS,11bS)-7,7a,8,9,10,11,11a,11b-octahydro-11b-hydroxy-alpha,alpha,8,8,11a-pentamethyl-6H-naphth[1,2-d]azepine-4-methanol|triptotin J

C20H31NO2 (317.2355)


   
   

1-Methyl-2-[9-(2-methoxyphenyl)nonyl]pyrrolidine

1-Methyl-2-[9-(2-methoxyphenyl)nonyl]pyrrolidine

C21H35NO (317.2719)


   

(2E,4E)-N-[(4-hydroxy-3-methoxyphenyl)ethyl]-2,4-decadienamide

(2E,4E)-N-[(4-hydroxy-3-methoxyphenyl)ethyl]-2,4-decadienamide

C19H27NO3 (317.1991)


A natural product found in Piper boehmeriaefolium.

   

batzellaside B

batzellaside B

C17H35NO4 (317.2566)


   
   
   
   
   
   
   
   
   
   
   

DTXSID00694029

DTXSID00694029

C21H35NO (317.2719)


   
   
   
   

Nateglinide

Nateglinide (Starlix)

C19H27NO3 (317.1991)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98079 - Meglitinide Antidiabetic Agent A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins D007004 - Hypoglycemic Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3289

   

2-benzyl-1-methyl-5-nonylpyrrolidin-3-ol

NCGC00385689-01!2-benzyl-1-methyl-5-nonylpyrrolidin-3-ol

C21H35NO (317.2719)


   
   
   
   
   
   
   
   

Trihexyphenidyl N-oxide

Trihexyphenidyl N-oxide

C20H31NO2 (317.2355)


   

Hydroxytrihexyphenidyl

Hydroxytrihexyphenidyl

C20H31NO2 (317.2355)


   

N-methyl arachidonoylamide

N-methyl-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C21H35NO (317.2719)


   

N-phenethyltridecanamide

N-phenethyltridecanamide

C21H35NO (317.2719)


   
   

Amorolfine

Amorolfine

C21H35NO (317.2719)


D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents

   

NA 21:4

N-methyl-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C21H35NO (317.2719)


   
   

4-Aza-5a-androstan-1-ene-3-one-17b-carboxylic acid

4-Aza-5a-androstan-1-ene-3-one-17b-carboxylic acid

C19H27NO3 (317.1991)


   

4-(Morpholine-4-carbonyl)phenylboronic Acid Pinacol Ester

4-(Morpholine-4-carbonyl)phenylboronic Acid Pinacol Ester

C17H24BNO4 (317.1798)


   

Amorolfine hydrochloride

Amorolfine hydrochloride

C21H35NO (317.2719)


   

4-METHYL-3-PYRROLIDIN-1-YLMETHYL-PIPERAZINE-1-CARBOXYLICACIDBENZYLESTER

4-METHYL-3-PYRROLIDIN-1-YLMETHYL-PIPERAZINE-1-CARBOXYLICACIDBENZYLESTER

C18H27N3O2 (317.2103)


   

BENZYL-[2-(4-BENZYLOXY-PHENYL)-ETHYL]-AMINE

BENZYL-[2-(4-BENZYLOXY-PHENYL)-ETHYL]-AMINE

C22H23NO (317.178)


   

4-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)MORPHOLINE

4-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)MORPHOLINE

C18H28BNO3 (317.2162)


   

1-ETHYL-4-(5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE

1-ETHYL-4-(5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE

C17H28BN3O2 (317.2274)


   

N-cyclohexyl-2-nitro-4-((piperidin-1-yl)methyl)benzenamine

N-cyclohexyl-2-nitro-4-((piperidin-1-yl)methyl)benzenamine

C18H27N3O2 (317.2103)


   

(4-BENZYLOXYBENZYL)-(1-PHENYL-ETHYL)AMINE

(4-BENZYLOXYBENZYL)-(1-PHENYL-ETHYL)AMINE

C22H23NO (317.178)


   

MORPHOLINO(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANONE

MORPHOLINO(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANONE

C17H24BNO4 (317.1798)


   

N,N-diethyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

N,N-diethyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

C18H28BNO3 (317.2162)


   

N-tert-Butyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

N-tert-Butyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

C18H28BNO3 (317.2162)


   

4-CYANO-3-FLUOROPHENYL TRANS-4-PENTYLCYCLOHEXANECARBOXYLATE

4-CYANO-3-FLUOROPHENYL TRANS-4-PENTYLCYCLOHEXANECARBOXYLATE

C19H24FNO2 (317.1791)


   

N-(2-Methoxyphenyl)-2-(di-t-butylphosphino)pyrrole

N-(2-Methoxyphenyl)-2-(di-t-butylphosphino)pyrrole

C19H28NOP (317.1908)


   

Dicyclohexyl(4-(N,N-dimethylamino)phenyl)phosphine

Dicyclohexyl(4-(N,N-dimethylamino)phenyl)phosphine

C20H32NP (317.2272)


   

methyl methyl undecylidene aminobenzoate

methyl methyl undecylidene aminobenzoate

C20H31NO2 (317.2355)


   

(±)-Tetrabenazine

(±)-Tetrabenazine

C19H27NO3 (317.1991)


   

N,N-DIETHYL-2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETAMIDE

N,N-DIETHYL-2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETAMIDE

C18H28BNO3 (317.2162)


   
   

(4aR,4bS,6aS,7S,9aS,9bS)-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid

(4aR,4bS,6aS,7S,9aS,9bS)-4a,6a-dimethyl-2-oxo-2,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid

C19H27NO3 (317.1991)


   

1-(2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOXY)ETHYL)PYRROLIDINE

1-(2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOXY)ETHYL)PYRROLIDINE

C18H28BNO3 (317.2162)


   

4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)Morpholine

4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)Morpholine

C18H28BNO3 (317.2162)


   

2-[(4-phenylpiperidin-1-yl)methyl]quinolin-6-amine

2-[(4-phenylpiperidin-1-yl)methyl]quinolin-6-amine

C21H23N3 (317.1892)


   

(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one

(3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one

C19H27NO3 (317.1991)


N - Nervous system

   

2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate

2-(4-Morpholino)ethyl-1-phenylcyclohexane-1-carboxylate

C19H27NO3 (317.1991)


   

(L)-Suberyl Carnitine

(3R)-3-[(7-Carboxyheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


   

(3S,11bS)-tetrabenazine

(3S,11bS)-tetrabenazine

C19H27NO3 (317.1991)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators C471 - Enzyme Inhibitor

   

Terodiline hydrochloride

Terodiline hydrochloride

C20H28ClN (317.191)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

2-{[4-(Methylethyl)cyclohexyl]carbonylamino}-3-phenylpropanoic acid

2-{[4-(Methylethyl)cyclohexyl]carbonylamino}-3-phenylpropanoic acid

C19H27NO3 (317.1991)


   

ent-Nateglinide

ent-Nateglinide

C19H27NO3 (317.1991)


   

Alverine hydrochloride

Alverine hydrochloride

C20H28ClN (317.191)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

(E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one

(E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one

C22H23NO (317.178)


   

L-Seryl-L-leucyl-L-valine

L-Seryl-L-leucyl-L-valine

C14H27N3O5 (317.1951)


   

1-Tert-butyl-5-[2-oxo-2-(1-piperidinyl)ethyl]-4-pyrazolo[3,4-d]pyrimidinone

1-Tert-butyl-5-[2-oxo-2-(1-piperidinyl)ethyl]-4-pyrazolo[3,4-d]pyrimidinone

C16H23N5O2 (317.1852)


   

4,17alpha-Dimethyl-4-aza-5-androsten-17beta-ol-3-one

4,17alpha-Dimethyl-4-aza-5-androsten-17beta-ol-3-one

C20H31NO2 (317.2355)


   

Austedo

Austedo

C19H27NO3 (317.1991)


C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system

   

1-(Phenylmethyl)cyclopentyl[(1S)-1-formylpentyl]carbamate

1-(Phenylmethyl)cyclopentyl[(1S)-1-formylpentyl]carbamate

C19H27NO3 (317.1991)


   

TETRABENAZINE

TETRABENAZINE

C19H27NO3 (317.1991)


D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators N - Nervous system Same as: D08575

   

Arachidonoyl-N-methyl amide

Arachidonoyl-N-methyl amide

C21H35NO (317.2719)


   

ent-7alpha-hydroxykaur-16-en-19-oate

ent-7alpha-hydroxykaur-16-en-19-oate

C20H29O3- (317.2117)


   

18R-hydroxy-eicosapentaenoate

18R-hydroxy-eicosapentaenoate

C20H29O3- (317.2117)


   

epi-leukotriene A4

epi-leukotriene A4

C20H29O3- (317.2117)


   
   

15-oxo-ETE(1-)

15-oxo-ETE(1-)

C20H29O3- (317.2117)


A polyunsaturated oxo fatty acid anion that is the conjugate base of 15-oxo-ETE.

   

(5Z,9E,11Z,14Z)-8-oxoicosa-5,9,11,14-tetraenoate

(5Z,9E,11Z,14Z)-8-oxoicosa-5,9,11,14-tetraenoate

C20H29O3- (317.2117)


   

12-oxo-ETE(1-)

12-oxo-ETE(1-)

C20H29O3- (317.2117)


A oxo fatty acid anion that is the conjugate base of 12-oxo-ETE, obtained by deprotonation of the carboxy group.

   

kauralexin A3

kauralexin A3

C20H29O3- (317.2117)


   

(11S,16S)-ent-kauran-11,16-epoxy-19-oate

(11S,16S)-ent-kauran-11,16-epoxy-19-oate

C20H29O3- (317.2117)


   

(2S,3S,7R)-2,3-diamino-8-(1-carbamoyl-2-iminoimidazolidin-4-yl)-7-hydroxyoctanoate

(2S,3S,7R)-2,3-diamino-8-(1-carbamoyl-2-iminoimidazolidin-4-yl)-7-hydroxyoctanoate

C12H25N6O4+ (317.1937)


   

(8Z,11Z,14Z,17Z)-3-oxo-icosa-8,11,14,17-tetraenoate

(8Z,11Z,14Z,17Z)-3-oxo-icosa-8,11,14,17-tetraenoate

C20H29O3- (317.2117)


   

2-[(11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]acetaldehyde

2-[(11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]acetaldehyde

C19H27NO3 (317.1991)


   

3-methylheptanedioylcarnitine

3-methylheptanedioylcarnitine

C15H27NO6 (317.1838)


   

2,4-dimethylhexanedioylcarnitine

2,4-dimethylhexanedioylcarnitine

C15H27NO6 (317.1838)


   

leukotriene A4(1-)

leukotriene A4(1-)

C20H29O3- (317.2117)


The leukotriene anion that is the conjugate base of leukotriene A4 arising from deprotonation of the carboxylic acid group. Major microspecies at pH 7.3.

   

Leu-Val-Ser

Leu-Val-Ser

C14H27N3O5 (317.1951)


A tripeptide composed of L-leucine, L-valine and L-serine joined in sequence by peptide linkages.

   

Aculene B

Aculene B

C19H27NO3 (317.1991)


A carboxylic ester resulting from the formal condensation of the hydroxy group of aculene D with the carboxylic acid group of L-proline. It is a sesquiterpenoid isolated from the fungus Aspergillus aculeatus.

   

5-oxo-ETE(1-)

5-oxo-ETE(1-)

C20H29O3- (317.2117)


A long-chain fatty acid anion that is the conjugate base of 5-oxo-ETE, obtained by deprotonation of the carboxy group.

   

1-(2-Phenylethyl)-3-[(4-propylcyclohexylidene)amino]thiourea

1-(2-Phenylethyl)-3-[(4-propylcyclohexylidene)amino]thiourea

C18H27N3S (317.1926)


   

15(R)-Hepe(1-)

15(R)-Hepe(1-)

C20H29O3- (317.2117)


An icosanoid anion that is the conjugate base of 15(R)-HEPE arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

(5Z,8Z,11Z,14Z,16E)-18-hydroxyicosa-5,8,11,14,16-pentaenoate

(5Z,8Z,11Z,14Z,16E)-18-hydroxyicosa-5,8,11,14,16-pentaenoate

C20H29O3- (317.2117)


   

2-phenyl-N-(2-(pyrrolidin-1-yl)ethyl)quinolin-4-amine

2-phenyl-N-(2-(pyrrolidin-1-yl)ethyl)quinolin-4-amine

C21H23N3 (317.1892)


   

N-(p-octylbenzoyl)-piperidin-4-ol

N-(p-octylbenzoyl)-piperidin-4-ol

C20H31NO2 (317.2355)


   
   

20-Oxoarachidonate

20-Oxoarachidonate

C20H29O3- (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of 20-oxoarachidonic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

eoxin A4(1-)

eoxin A4(1-)

C20H29O3- (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of eoxin A4, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

17(S),18(R)-EETeTr(1-)

17(S),18(R)-EETeTr(1-)

C20H29O3- (317.2117)


A 17,18-EETeTr(1-) in which the epoxy group has (17S,18R)-configuration.

   

11-oxo-ETE(1-)

11-oxo-ETE(1-)

C20H29O3- (317.2117)


A polyunsaturated oxo fatty acid anion that is the conjugate base of 11-oxo-ETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-cycloheptyl-4-(2-oxolanylmethoxy)benzamide

N-cycloheptyl-4-(2-oxolanylmethoxy)benzamide

C19H27NO3 (317.1991)


   

17,18-EETeTr(1-)

17,18-EETeTr(1-)

C20H29O3- (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of 17,18-EETeTr, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoate

(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoate

C20H29O3- (317.2117)


   

(5Z,8Z,11Z,14Z,17Z)-20-hydroxyicosa-5,8,11,14,17-pentaenoate

(5Z,8Z,11Z,14Z,17Z)-20-hydroxyicosa-5,8,11,14,17-pentaenoate

C20H29O3- (317.2117)


   

11(R)-Hepe(1-)

11(R)-Hepe(1-)

C20H29O3- (317.2117)


An icosanoid anion that is the conjugate base of 11(R)-HEPE arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

(5Z,8Z,11Z,14Z,17Z)-19-hydroxyicosa-5,8,11,14,17-pentaenoate

(5Z,8Z,11Z,14Z,17Z)-19-hydroxyicosa-5,8,11,14,17-pentaenoate

C20H29O3- (317.2117)


   

18(S)-Hepe(1-)

18(S)-Hepe(1-)

C20H29O3- (317.2117)


An 18-HEPE(1-) that is the conjugate base of 18(S)-HEPE, arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

15(S)-Hepe(1-)

15(S)-Hepe(1-)

C20H29O3- (317.2117)


A HEPE(1-) that is the conjugate base of 15(S)-HEPE, arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

17(R),18(S)-EETeTr(1-)

17(R),18(S)-EETeTr(1-)

C20H29O3- (317.2117)


A 17,18-EETeTr(1-) in which the epoxy group has (17R,18S)-configuration.

   

N-[2-(1-cyclohexenyl)ethyl]-3-[(4-methylphenyl)methylthio]propanamide

N-[2-(1-cyclohexenyl)ethyl]-3-[(4-methylphenyl)methylthio]propanamide

C19H27NOS (317.1813)


   

8,9-epoxy-(5Z,11Z,14Z,17Z)-eicosatetraenoate

8,9-epoxy-(5Z,11Z,14Z,17Z)-eicosatetraenoate

C20H29O3- (317.2117)


   

(5Z)-7-{(2R,3Z)-3-[(2Z,5Z)-undeca-2,5-dien-1-ylidene]oxiran-2-yl}hept-5-enoate

(5Z)-7-{(2R,3Z)-3-[(2Z,5Z)-undeca-2,5-dien-1-ylidene]oxiran-2-yl}hept-5-enoate

C20H29O3- (317.2117)


   

14,15-Epoxy-(5Z,8Z,11Z,17Z)-eicosatetraenoate

14,15-Epoxy-(5Z,8Z,11Z,17Z)-eicosatetraenoate

C20H29O3- (317.2117)


   

(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoate

(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoate

C20H29O3- (317.2117)


   

11,12-epoxy-(5Z,8Z,14Z,17Z)-eicosatetraenoate

11,12-epoxy-(5Z,8Z,14Z,17Z)-eicosatetraenoate

C20H29O3- (317.2117)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(5Z,7E,11Z,14Z)-9-oxoicosa-5,7,11,14-tetraenoate

(5Z,7E,11Z,14Z)-9-oxoicosa-5,7,11,14-tetraenoate

C20H29O3- (317.2117)


   

10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]decanoate

10-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]decanoate

C16H29O6- (317.1964)


   

(5Z,7E,11Z,14Z,17Z)-9-hydroxyicosa-5,7,11,14,17-pentaenoate

(5Z,7E,11Z,14Z,17Z)-9-hydroxyicosa-5,7,11,14,17-pentaenoate

C20H29O3- (317.2117)


   

(2S)-2,6-bis[(3R)-3-aminobutanamido]hexanoate

(2S)-2,6-bis[(3R)-3-aminobutanamido]hexanoate

C14H29N4O4+ (317.2189)


   

4-Hydroxy-all-trans-13,14-dihydroretinoate

4-Hydroxy-all-trans-13,14-dihydroretinoate

C20H29O3- (317.2117)


   

12(S)-Hepe(1-)

12(S)-Hepe(1-)

C20H29O3- (317.2117)


   

(9R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydecanoate

(9R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxydecanoate

C16H29O6- (317.1964)


   

5(S)-Hepe(1-)

5(S)-Hepe(1-)

C20H29O3- (317.2117)


   

(3Z,6Z,9Z,12Z,15Z)-N-(2-hydroxyethyl)octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-(2-hydroxyethyl)octadeca-3,6,9,12,15-pentaenamide

C20H31NO2 (317.2355)


   

N-Benzyl-3-cyclohexaencarbonyloxy-2,2-dimethylpropanamide

N-Benzyl-3-cyclohexaencarbonyloxy-2,2-dimethylpropanamide

C19H27NO3 (317.1991)


   

butenafine

butenafine

C23H27N (317.2143)


D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

   

O-suberoylcarnitine

O-suberoylcarnitine

C15H27NO6 (317.1838)


An O-acylcarnitine having suberoyl (7-carboxyheptanoyl) as the acyl substituent.

   

3-Hydroxynonanoylcarnitine

3-Hydroxynonanoylcarnitine

C16H31NO5 (317.2202)


   

19-HEPE(1-)

19-HEPE(1-)

C20H29O3 (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of 19-HEPE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoate

(5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoate

C20H29O3 (317.2117)


An EpETE(1-) that is the conjugate base of (5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5Z,8R,9Z,11Z,14Z)-8,9-epoxyicosatetraenoate

(5Z,8R,9Z,11Z,14Z)-8,9-epoxyicosatetraenoate

C20H29O3 (317.2117)


An EpETE(1-) that is the conjugate base of (5Z,8R,9Z,11Z,14Z)-8,9-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

17beta-Hydroxy-4,17-dimethyl-4-azaandrost-5-en-3-one

17beta-Hydroxy-4,17-dimethyl-4-azaandrost-5-en-3-one

C20H31NO2 (317.2355)


   

(3R)-3-[(7-Carboxyheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

(3R)-3-[(7-Carboxyheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO6 (317.1838)


   

9-HEPE(1-)

9-HEPE(1-)

C20H29O3 (317.2117)


A HEPE(1-) that is the conjugate base of 9-HEPE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#16(1-)

ascr#16(1-)

C16H29O6 (317.1964)


Conjugate base of ascr#16

   

8-oxo-ETE(1-)

8-oxo-ETE(1-)

C20H29O3 (317.2117)


An unsaturated fatty acid anion that is the conjugate base of 8-KETE, obtained by deprotonation of the carboxy group.

   

5-HEPE(1-)

5-HEPE(1-)

C20H29O3 (317.2117)


An icosanoid anion that is the conjugate base of 5-HEPE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

18(R)-HEPE(1-)

18(R)-HEPE(1-)

C20H29O3 (317.2117)


An icosanoid anion that is the conjugate base of 18(R)-HEPE arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

18-HEPE(1-)

18-HEPE(1-)

C20H29O3 (317.2117)


An icosanoid anion that is the conjugate base of 18-HEPE, arising from deprotonation of the carboxylic acid group; major species at pH 7.3.

   

oscr#16(1-)

oscr#16(1-)

C16H29O6 (317.1964)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#16, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

20-HEPE(1-)

20-HEPE(1-)

C20H29O3 (317.2117)


A polyunsaturated fatty acid anion that is the conjugate base of 20-HEPE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

12-HEPE(1-)

12-HEPE(1-)

C20H29O3 (317.2117)


A HEPE(1-) that is the conjugate base of 12-HEPE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoate

(5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoate

C20H29O3 (317.2117)


An EpETE(1-) that is the conjugate base of (5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5Z,8Z,11Z,17Z)-14,15-Epoxyicosatetraenoate

(5Z,8Z,11Z,17Z)-14,15-Epoxyicosatetraenoate

C20H29O3 (317.2117)


An EpETE(1-) that is the conjugate base of (5Z,8Z,11Z,17Z)-14,15-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   
   
   

(2z,4e)-6,7-dihydroxy-3,7,11-trimethyl-1-(1h-pyrrol-2-yl)dodeca-2,4,10-trien-1-one

(2z,4e)-6,7-dihydroxy-3,7,11-trimethyl-1-(1h-pyrrol-2-yl)dodeca-2,4,10-trien-1-one

C19H27NO3 (317.1991)


   

1-ethyl-3a,6-dimethyl-3-oxo-4,5,8,8a-tetrahydroazulen-4-yl pyrrolidine-2-carboxylate

1-ethyl-3a,6-dimethyl-3-oxo-4,5,8,8a-tetrahydroazulen-4-yl pyrrolidine-2-carboxylate

C19H27NO3 (317.1991)


   

mycalenitrile-17

mycalenitrile-17

C21H35NO (317.2719)


   

2-{3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}acetaldehyde

2-{3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}acetaldehyde

C19H27NO3 (317.1991)


   

(8s,9as,13as)-4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

(8s,9as,13as)-4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

C19H27NO3 (317.1991)


   

13,16-dimethyl-18-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.2.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]nonadeca-2(14),3(11),5(10),6,8,12-hexaene

13,16-dimethyl-18-(prop-1-en-2-yl)-15-oxa-4-azapentacyclo[14.2.1.0²,¹⁴.0³,¹¹.0⁵,¹⁰]nonadeca-2(14),3(11),5(10),6,8,12-hexaene

C22H23NO (317.178)


   

mycalenitrile-18

mycalenitrile-18

C21H35NO (317.2719)


   

1-[(1s,3as,3br,5as,7r,9ar,9br,11as)-7-amino-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3br,5as,7r,9ar,9br,11as)-7-amino-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl]ethanone

C21H35NO (317.2719)


   

(3ar,4s,8ar)-1-ethyl-3a,6-dimethyl-3-oxo-4,5,8,8a-tetrahydroazulen-4-yl (2s)-pyrrolidine-2-carboxylate

(3ar,4s,8ar)-1-ethyl-3a,6-dimethyl-3-oxo-4,5,8,8a-tetrahydroazulen-4-yl (2s)-pyrrolidine-2-carboxylate

C19H27NO3 (317.1991)


   

(1s,3as,3br,5as,9as,9bs,11as)-1-[(1s)-1-aminoethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

(1s,3as,3br,5as,9as,9bs,11as)-1-[(1s)-1-aminoethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

C21H35NO (317.2719)


   

3,10-dimethyl-3-(3-methylbut-2-en-1-yl)-6h-pyrano[2,3-c]carbazole

3,10-dimethyl-3-(3-methylbut-2-en-1-yl)-6h-pyrano[2,3-c]carbazole

C22H23NO (317.178)


   

(2r)-2-[9-(2-methoxyphenyl)nonyl]-1-methylpyrrolidine

(2r)-2-[9-(2-methoxyphenyl)nonyl]-1-methylpyrrolidine

C21H35NO (317.2719)


   

(2s)-2-{[(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-3-methylbutylidene]amino}-3-hydroxypropanoic acid

(2s)-2-{[(2s)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-3-methylbutylidene]amino}-3-hydroxypropanoic acid

C14H27N3O5 (317.1951)


   

1-[(2s,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]ethanone

1-[(2s,3r,11bs)-3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl]ethanone

C19H27NO3 (317.1991)


   

1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,8h,9h,10h-cyclohepta[d]isoindol-11-one

1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,8h,9h,10h-cyclohepta[d]isoindol-11-one

C20H31NO2 (317.2355)


   

6,7-dihydroxy-3,7,11-trimethyl-1-(1h-pyrrol-2-yl)dodeca-2,4,10-trien-1-one

6,7-dihydroxy-3,7,11-trimethyl-1-(1h-pyrrol-2-yl)dodeca-2,4,10-trien-1-one

C19H27NO3 (317.1991)


   

1-(1-aminoethyl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

1-(1-aminoethyl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

C21H35NO (317.2719)


   

(7as,11as,11bs)-4-(2-hydroxypropan-2-yl)-8,8,11a-trimethyl-6h,7h,7ah,9h,10h,11h-naphtho[1,2-d]azepin-11b-ol

(7as,11as,11bs)-4-(2-hydroxypropan-2-yl)-8,8,11a-trimethyl-6h,7h,7ah,9h,10h,11h-naphtho[1,2-d]azepin-11b-ol

C20H31NO2 (317.2355)


   

4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

C19H27NO3 (317.1991)


   

(1s,3as,5as,9as,9bs,11as)-1-[(1s)-1-aminoethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

(1s,3as,5as,9as,9bs,11as)-1-[(1s)-1-aminoethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-7-one

C21H35NO (317.2719)


   

(2e,4e,9e,12e)-n-(2-methylbutyl)hexadeca-2,4,9,12-tetraenimidic acid

(2e,4e,9e,12e)-n-(2-methylbutyl)hexadeca-2,4,9,12-tetraenimidic acid

C21H35NO (317.2719)


   

(1s,10r)-10-heptyl-6-methyl-7,9,12-triazatricyclo[6.3.1.0⁴,¹²]dodeca-4,6,8-triene-5-carboxylic acid

(1s,10r)-10-heptyl-6-methyl-7,9,12-triazatricyclo[6.3.1.0⁴,¹²]dodeca-4,6,8-triene-5-carboxylic acid

C18H27N3O2 (317.2103)


   

4-(2-hydroxypropan-2-yl)-8,8,11a-trimethyl-6h,7h,7ah,9h,10h,11h-naphtho[1,2-d]azepin-11b-ol

4-(2-hydroxypropan-2-yl)-8,8,11a-trimethyl-6h,7h,7ah,9h,10h,11h-naphtho[1,2-d]azepin-11b-ol

C20H31NO2 (317.2355)


   

(2s,3s,6r)-2-benzyl-1-methyl-6-octylpiperidin-3-ol

(2s,3s,6r)-2-benzyl-1-methyl-6-octylpiperidin-3-ol

C21H35NO (317.2719)


   

(2r,3s,4s,6s)-2-(hydroxymethyl)-6-(2-hydroxyundecyl)piperidine-3,4-diol

(2r,3s,4s,6s)-2-(hydroxymethyl)-6-(2-hydroxyundecyl)piperidine-3,4-diol

C17H35NO4 (317.2566)


   

1-{3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}ethanone

1-{3-ethyl-9,10-dimethoxy-1h,2h,3h,4h,6h,7h,11bh-pyrido[2,1-a]isoquinolin-2-yl}ethanone

C19H27NO3 (317.1991)


   

(2r,3r,6s)-2-methyl-6-(9-phenylnonyl)piperidin-3-ol

(2r,3r,6s)-2-methyl-6-(9-phenylnonyl)piperidin-3-ol

C21H35NO (317.2719)


   

11'-methoxy-6'-methyl-6'-azaspiro[cyclohexane-1,2'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(12'),9'(13'),10'-triene-4,12'-diol

11'-methoxy-6'-methyl-6'-azaspiro[cyclohexane-1,2'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(12'),9'(13'),10'-triene-4,12'-diol

C19H27NO3 (317.1991)


   

(3s,3ar,4s,6as,8s,11ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,8h,9h,10h-cyclohepta[d]isoindol-11-one

(3s,3ar,4s,6as,8s,11ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,7h,8h,9h,10h-cyclohepta[d]isoindol-11-one

C20H31NO2 (317.2355)


   

(8r,9ar,13ar)-4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

(8r,9ar,13ar)-4,11-dimethyl-13-oxo-1h,2h,3h,5h,6h,8h,9h,9ah,10h-indeno[1,7a-e]azonin-8-yl acetate

C19H27NO3 (317.1991)